← Back to Search

Diets for Multiple Sclerosis (Waves Trial)

N/A
Waitlist Available
Led By Linda Snetselaar, PhD, RD,
Research Sponsored by Terry L. Wahls
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Fatigue as documented by a Fatigue Severity Scale score of greater than or equal to 4
Between the ages of 18 and 70
Must not have
Taking insulin or Coumadin
Unwilling to have blood drawn
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12-36 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare two diets for their effect on fatigue in people with relapsing-remitting multiple sclerosis.

Who is the study for?
This trial is for adults aged 18-70 with relapsing-remitting multiple sclerosis and fatigue, willing to eat meat and more vegetables while cutting out comfort foods. Participants must not be pregnant or planning pregnancy, able to walk with minimal support, and capable of preparing meals according to diet guidelines.
What is being tested?
The study compares the Swank Diet (low in saturated fat) against the Wahls Elimination Diet (modified paleo) on reducing fatigue in multiple sclerosis patients. After a 12-week period of usual diet, participants are randomly assigned one of the diets for 24 weeks.
What are the potential side effects?
Potential side effects may include digestive changes due to new dietary habits. As these are diets focused on natural foods, severe side effects are unlikely but could involve nutrient deficiencies if not followed correctly.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I often feel very tired.
Select...
I am between 18 and 70 years old.
Select...
I have had gastric bypass surgery and my doctor confirms I am weight stable and suitable for this study.
Select...
I can walk 25 feet by myself or with a cane.
Select...
My neurologist confirmed I have Relapsing-Remitting MS.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking insulin or Coumadin.
Select...
I am not willing to have my blood drawn.
Select...
I have been treated for a cancer other than skin cancer in the last year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12-36 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12-36 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Fatigue
Fatigue
Secondary study objectives
Change in cognitive function
Body Weight Changes
Change in gait (walk)
+8 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Wahls Elimination DietExperimental Treatment1 Intervention
Individuals randomized to this arm will follow a modified paleolithic diet that eliminates all grains, dairy, eggs, legumes, and nightshade vegetables/spices starting at week 12.
Group II: Swank DietExperimental Treatment1 Intervention
Individuals randomized to this arm will follow a low saturated fat diet starting at week 12.

Find a Location

Who is running the clinical trial?

Terry L. WahlsLead Sponsor
5 Previous Clinical Trials
301 Total Patients Enrolled
4 Trials studying Multiple Sclerosis
301 Patients Enrolled for Multiple Sclerosis
National Multiple Sclerosis SocietyOTHER
97 Previous Clinical Trials
9,564 Total Patients Enrolled
95 Trials studying Multiple Sclerosis
9,210 Patients Enrolled for Multiple Sclerosis
Linda Snetselaar, PhD, RD,Principal InvestigatorUniversity of Iowa

Media Library

Swank Diet Clinical Trial Eligibility Overview. Trial Name: NCT02914964 — N/A
Multiple Sclerosis Research Study Groups: Swank Diet, Wahls Elimination Diet
Multiple Sclerosis Clinical Trial 2023: Swank Diet Highlights & Side Effects. Trial Name: NCT02914964 — N/A
Swank Diet 2023 Treatment Timeline for Medical Study. Trial Name: NCT02914964 — N/A
~11 spots leftby Nov 2025